95-10079. Availability of Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patents Concerning Anticonvulsant and Neuroprotective Agents

[Federal Register Volume 60, Number 79 (Tuesday, April 25, 1995)]
[Notices]
[Page 20259]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10079]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability of Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patents Concerning Anticonvulsant and Neuroprotective 
Agents

AGENCY: U.S. Army Medical Research and Materiel Command, Department of 
the Army, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S. Patent No. 5,258,386 entitled ``(+)-
3-Substituted-N-Alkylmorphinans, Synthesis and use as Anticonvulsant 
and Neuroprotective Agents'' and issued on November 1, 1993, and U.S. 
Patent No. 5,331,010 entitled ``1-Phenylalkanecarboxylic Acid 
Derivatives as Anticonvulsant and Neuroprotective Agents; and issued on 
July 19, 1994. These patents have been assigned to the United States 
Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-
5012.

FOR FURTHER INFORMATION CONTACT:
Mr. John F. Moran, Patent Attorney, [phone] or telefax (301) 
619-7714.

SUPPLEMENTARY INFORMATION: The inventions represent discoveries that 
members of certain classes of compounds [(+)-3-substituted-N-
alkylmorphinans and 1-phenylalkanecarboxylic acids] possess effective 
usefulness as nonaddictive anticonvulsant and neuroprotective agents. 
The 1-phenylalkanecarboxylic acids include novel non-opiate derivatives 
as well as previously published species. Methods for controlling 
convulsions in a variety of pharmaceutical formulations and modalities 
are described. In both inventions, novel compounds which possess these 
biological properties are presented in a method or methods of use for 
preventing, treating, or controlling convulsions in mammals having a 
need for such treatment. The compounds do not lead to dependency, have 
low toxicity, and provide effective anticonvulsant or neuroprotective 
treatment with little or no behavioral detriment to the recipient.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 95-10079 Filed 4-24-95; 8:45 am]
BILLING CODE 3710-08-M